Merck (MRK) stock nudges up after-hours as Health Canada clears Keytruda SC shot
Merck shares rose 0.2% in after-hours trading after Health Canada approved Keytruda SC, an under-the-skin version of its cancer drug, for all indications cleared for IV Keytruda. The new shot can be administered in one to two minutes, compared to a 30-minute infusion. Merck said launch timing in Canada depends on provincial reimbursement decisions.